In the last trading session, 1.6 million Emergent Biosolutions Inc (NYSE:EBS) shares changed hands as the company’s beta touched 1.00. With the company’s per share price at $2.05 changed hands at -$0.07 or -3.30% during last session, the market valuation stood at $106.21M. EBS’s last price was a discount, traded about -712.68% off its 52-week high of $16.66. The share price had its 52-week low at $1.81, which suggests the last value was 11.71% up since then. When we look at Emergent Biosolutions Inc’s average trading volume, we note the 10-day average is 1.54 million shares, with the 3-month average coming to 2.25 million.
Analysts gave the Emergent Biosolutions Inc (EBS) stock a consensus recommendation rating of an Overweight, calculated at a mean rating of 2.33. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended EBS as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Emergent Biosolutions Inc’s EPS for the current quarter is expected to be -$0.22.
Emergent Biosolutions Inc (NYSE:EBS) trade information
Instantly EBS was in red as seen at the end of in last trading. With action 2.50%, the performance over the past five days has been green. The drop to weekly highs of 2.43 on Friday, 11/17/23 subtracted -3.30% to the stock’s daily price. The company’s shares are showing year-to-date downside of -82.64%, with the 5-day performance at 2.50% in the green. However, in the 30-day time frame, Emergent Biosolutions Inc (NYSE:EBS) is -7.66% down. Looking at the short shares, we see there were 10.93 million shares sold at short interest cover period of 7.87 days.
The consensus price target for the stock as assigned by Wall Street analysts is $6.00, meaning bulls need an upside of 65.83% from its current market value. According to analyst projections, EBS’s forecast low is $5.00 with $7.00 as the target high. To hit the forecast high, the stock’s price needs a -241.46% plunge from its current level, while the stock would need to soar -143.9% for it to hit the projected low.
Emergent Biosolutions Inc (EBS) estimates and forecasts
Data shows that the Emergent Biosolutions Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -74.91% over the past 6 months, a -45.29% in annual growth rate that is considerably lower than the industry average of 14.90%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Emergent Biosolutions Inc will rise 82.70%, while the growth in revenue is estimated to hit 177.40% for the next quarter. Year-over-year growth is forecast to reach -4.80% down from the last financial year.
Consensus estimates given by 3 financial analysts project the company’s revenue in the current quarter to hit an average of $237.43 million. 3 analysts are of the opinion that Emergent Biosolutions Inc’s revenue for the quarter ending Dec 2023 will be $295.53 million. The company’s revenue for the corresponding quarters a year ago was $268.3 million and $330.7 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -11.50%. The estimates for the next quarter sales put growth at -10.60%.
The 2023 estimates are for Emergent Biosolutions Inc earnings to decrease by -93.57%.
Emergent Biosolutions Inc is expected to release its next quarterly earnings report on November 08.
Emergent Biosolutions Inc (NYSE:EBS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 2.29% of Emergent Biosolutions Inc shares while 93.27% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 95.46%. There are 93.27% institutions holding the Emergent Biosolutions Inc stock share, with Blackrock Inc. the top institutional holder. As of Jun 29, 2023, the company held 17.82% of the shares, roughly 9.23 million EBS shares worth $67.85 million.
State Street Corporation holds the second largest percentage of outstanding shares, with 13.11% or 6.79 million shares worth $49.94 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Aug 30, 2023 were SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. With 4.9 million shares estimated at $22.99 million under it, the former controlled 9.46% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.79% of the shares, roughly 1.44 million shares worth around $10.61 million.